Siegfried Buys Two Spanish Sites From Novartis

Post-Acquisition, Company Expects 2021 Sales To Exceed $1bn

After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”

Spain
Siegfried lays out plan for its newly acquired manufacturing sites in Barcelona, Spain • Source: Shutterstock

With the aim of enhancing its global production network in terms of capacity and technological capabilities, Siegfried has announced the acquisition of two Novartis AG manufacturing facilities in Spain. Following the acquisition – which is expected to close by the end of the year – Siegfried is expecting the overall sales of the company to exceed CHF1bn ($1.09bn) in 2021.

According to the Swiss contract development and manufacturing organization, with this acquisition its drug product operations for finished dosage forms...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business